Respiratory Inhalers - Market Insights
An inhaler (puffer, spray or pump) is a medical device that is used for delivering medication into the body via lungs. It is used for releasing medication in the body to treat respiratory diseases such as bronchitis, asthma, allergic rhinitis, Chronic Obstructive Pulmonary Disorder (COPD), pneumonia, and sinusitis. All these diseases can significantly restrain the physical activities of the individual. The symptoms associated with mild and severe respiratory conditions include coughing, wheezing, chest pain, respiratory distress, and shortness of breath, congestion, and even death in some cases due to its severity. There are different types of inhalers such as metered-dose inhaler, dry powder inhalers, nebulizers, and others.
The global respiratory inhalers market was valued at US$ 30,639.9 million in 2018, and is expected to exhibit a CAGR of 5.7% over the forecast period (2019-2027).
Figure 1. Global Respiratory Inhalers Market Size and Forecast, US$ Million and Y-o-Y Growth (%), 2019–2027
Source: Coherent Market Insights Analysis (2019)
Increasing product launches, product approvals, and technological advancements by key players is expected to drive global respiratory inhalers market growth over the forecast period
Manufacturers are engaged in launching new products due to increasing demand of respiratory inhalers for treating several respiratory diseases. For instance, in April 2019, two new steroid inhalers were launched by Glenmark Pharmaceuticals, which includes Soprobec (beclometasone), a metered-dose aerosol inhaler and Stalpex (salmeterol/fluticasone), a breath-actuated inhaler.
Moreover, in 2017, Cipla Medpro (subsidiary of Cipla Ltd.) based in South Africa, launched Synchrobreathe in South Africa. Synchrobreathe is indicated for the treatment of obstructive airway diseases (OAD) such as asthma. Furthermore, in April 2019, Cipla Ltd launched Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, which can be used for the treatment of respiratory diseases such as obstructive airway diseases (OAD) that includes asthma and chronic obstructive pulmonary disorder (COPD).
In September 2017, GlaxoSmithKline plc received approval from U.S. Food and Drug Administration (FDA) for Trelegy Ellipta. Trelegy Ellipta, is the first once-daily use inhaler triple therapy (i.e. combination of 3 active molecules in a single inhaler) for the treatment of chronic obstructive pulmonary disease (COPD).
Increasing technological advancements adopted by key players is expected to increase the demand for digital inhalers (smart inhalers). Smart inhalers are available that includes embedded sensors with bluetooth technology. These devices also come up with touchscreens, audio visual medication reminders, and additional advantages such as mobile application connectivity, customized user interface options, and real time analysis through cloud based portals for researchers and clinicians. For instance, in September 2017, Adherium Ltd. a digital health technologies company, received the approval from the U.S Food and Drug Administration (FDA) for its SmartTouch inhaler monitoring device to be used with AstraZeneca’s Symbiocort aerosol inhaler. This is expected to drive the global respiratory inhalers market growth over the forecast period.
Increasing prevalence of respiratory diseases is expected to boost the global respiratory inhalers market growth
Increasing prevalence of respiratory diseases such as COPD, asthma, lower respiratory tract infection, and others is expected to drive the global respiratory inhalers growth over the forecast period. For instance, according to the European Respiratory Society 2017, globally about 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD) and about 334 million people suffer from asthma. Moreover, according to same source, globally 100 million people suffer from sleep-disordered breathing and over 50 million people suffer from occupational lung diseases (such as asthma, COPD, bronchiolitis obliterans and others).
Global Respiratory Inhalers Market - Regional Analysis
Among regions, North America is expected to hold dominant position in the global respiratory inhalers market growth over the forecast period, owing to increasing prevalence of chronic respiratory diseases such as asthma, COPD, and others. For instance, according to the Centers of Disease Control and Prevention (CDC), in U.S. 2018, around 1.3 million people suffered from Emphysema, 7.6 million people had asthma, and 3.4 million people suffered from chronic bronchitis. Such increasing prevalence of respiratory diseases is expected to increase demand of respiratory inhalers, which is further expected to drive global respiratory inhalers market growth over the forecast period.
Europe is also expected to witness a significant growth over the forecast period due to presence of key players such as Boehringer Ingelheim GmbH and AstraZeneca Plc. These players are focused on innovating new products and products approvals, which is expected to boost the global respiratory inhalers market growth. For instance in April 2016, AstraZeneca Plc., received European Commission (EC) approval for Bevespi Aerosphere, first product, which uses AstraZeneca’s Co-suspension technology that enables more than one medicine delivery from a single Metered Dose Inhaler (MDI).
Figure 2: Global Respiratory Inhalers Market Share (%), By Region, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Factors restraining the global respiratory inhalers market growth include availability of alternative treatment, such as small molecule drugs, herbs and vitamins. For instance, according to National Center for Biotechnology Information (NCBI), Chinese herb ding-chan tang (DCT) can decrease inflammation and relieve bronchospasm), there are also other treatments available such as Yoga (breathing exercises), natural remedies and others.
Key players operating in the global respiratory inhalers market include AstraZeneca Plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare, PARI Medical Holding, Teva Pharmaceutical Industries Ltd, and H&T Presspart.
Inhalers are devices that are used for delivering medicine through mouth to lungs for treating breathing difficulties in chronic respiratory diseases. Chronic respiratory diseases are the group of chronic diseases, which affect airways, lungs, and other parts of the respiratory system. Chronic respiratory diseases include asthma and respiratory allergies, chronic obstructive pulmonary disease (COPD), occupational lung diseases, sleep apnea syndrome, and pulmonary hypertension.
Increasing demand of respiratory inhalers is expected to drive the global respiratory inhalers market growth over the forecast period. In market there are several respiratory inhalers available with different shape and size as required for different medical conditions and different age group, which may create confusion in consumer mind to choose the best inhaler for them. For this manufacturers are focused on helping people by providing information about the respiratory inhalers, as it is very essential to choose appropriate asthma inhalers for patients. People consult with their doctors/ physician and get help of online applications or company website portals for choosing appropriate inhalers. For instance, in April 2019, National Institute for Health and Care Excellence published a new patient decision aid, to help patients in choosing the best asthma inhaler for them. It also includes information about ecofriendly inhalers, which is suggested for adoption by patients (if any substitute for particular inhalers are available). Such efforts by manufactures are expected to propel the global respiratory inhalers market growth over the forecast period.
Increasing product launches is expected to boost the global respiratory inhalers market growth over the forecast period. Manufacturers are focusing on developing new products and launches, in order to expand their product offerings. For instance, in January 2017, Teva Pharmaceutical Industries Ltd., launched ‘AirDuo RespiClick’ inhalation powder for the treatment of asthma in patients of age 12 years and older. ‘AirDuo RespiClick’ and its authorized generic (Fluticasone Propionate and Salmeterol) inhalation powder (multidose dry powder inhaler) are fixed-dose combination asthma therapies that contains an inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 34 market data tables and 25 figures on "Respiratory Inhalers Market - Global forecast to 2027”
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.